Estrella Immunopharma (ESLA) Restructuring Costs (2022 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Restructuring Costs of $149114.0 for Q1 2026, up 202.19% year-over-year from $49345.0 in Q1 2025, and up 413.02% quarter-over-quarter from $29066.0 in Q4 2025.
Estrella Immunopharma (ESLA) Restructuring Costs (2022 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Restructuring Costs for 5 consecutive years, with $149114.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Restructuring Costs rose 202.19% year-over-year to $149114.0; the TTM figure through Mar 2026 stood at $325906.0 (down 4.69% YoY), while the FY2025 annual figure was $226137.0, up 198.36% from the prior year.
- Restructuring Costs grew to $149114.0 in Q1 2026 per ESLA's latest filing, from $29066.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $706149.0 in Q4 2023 and bottomed at $29066.0 in Q4 2025.
- Historically, Restructuring Costs has averaged $144069.7 across 5 years, with a median of $97051.0 in 2024.
- Annual changes were most pronounced in 2023 — Restructuring Costs jumped 456.13% — and 2024, when it sank 89.27%.
- Estrella Immunopharma's Restructuring Costs stood at $126975.0 in 2022, then surged by 456.13% to $706149.0 in 2023, then tumbled by 89.27% to $75794.0 in 2024, then sank by 61.65% to $29066.0 in 2025, then jumped by 413.02% to $149114.0 in 2026.
- Business Quant data shows ESLA's Restructuring Costs at $149114.0 in Q1 2026, $29066.0 in Q4 2025, and $102965.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45,895.00 |
| Mar 31, 2026 | 149,114.00 |
| Dec 31, 2025 | 29,066.00 |
| Sep 30, 2025 | 102,965.00 |
| Jun 30, 2025 | 44,761.00 |
| Mar 31, 2025 | 49,345.00 |
| Dec 31, 2024 | 75,794.00 |
| Sep 30, 2024 | 125,673.00 |
| Jun 30, 2024 | 91,137.00 |
| Mar 31, 2024 | 37,395.00 |
| Dec 31, 2023 | 706,149.00 |
| Mar 31, 2023 | 190,462.00 |
| Dec 31, 2022 | 126,975.00 |